74,334 Shares of Cellebrite DI Ltd. $CLBT Purchased by Parthenon LLC

Parthenon LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 74,334 shares of the company’s stock, valued at approximately $837,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Elevation Wealth Partners LLC lifted its stake in Cellebrite DI by 93.3% in the 3rd quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company’s stock valued at $66,000 after buying an additional 2,816 shares in the last quarter. Tidal Investments LLC increased its stake in Cellebrite DI by 12.5% during the 2nd quarter. Tidal Investments LLC now owns 114,506 shares of the company’s stock worth $1,672,000 after buying an additional 12,749 shares in the last quarter. Nine Ten Capital Management LLC increased its stake in Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after buying an additional 682,933 shares in the last quarter. Light Street Capital Management LLC increased its stake in Cellebrite DI by 104.8% during the 2nd quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company’s stock worth $19,166,000 after buying an additional 671,830 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after acquiring an additional 1,475,579 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT traded up $0.31 during midday trading on Friday, hitting $12.10. The company had a trading volume of 1,393,646 shares, compared to its average volume of 2,009,846. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.98. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of 55.00, a price-to-earnings-growth ratio of 1.81 and a beta of 1.14. The business’s 50-day simple moving average is $11.40 and its 200-day simple moving average is $13.02.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CLBT shares. DA Davidson reissued a “buy” rating and issued a $15.00 price objective on shares of Cellebrite DI in a research note on Tuesday, September 15th. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday, August 14th. JPMorgan Chase & Co. reduced their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Finally, Lake Street Capital decreased their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.70.

Insider Buying and Selling

In other news, CMO David Gee sold 4,323 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $11.36, for a total transaction of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. The trade was a 3.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas E. Hogan sold 25,299 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the completion of the sale, the insider directly owned 765,249 shares of the company’s stock, valued at $8,639,661.21. This represents a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 196,870 shares of company stock valued at $2,797,143 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Cellebrite DI Profile

Cellebrite DI Ltd. (NASDAQ: CLBT) provides digital intelligence and digital forensics solutions that help organizations collect, preserve, analyze and manage data from mobile devices, computers, cloud environments and other digital sources. Its customers include law enforcement agencies, public safety organizations, government and intelligence bodies, military units, and corporate security and investigation teams.

The company’s offerings include tools for accessing and extracting digital evidence, case and evidence management, and investigative analytics.